diagnostic groups are heterogenous, with only six of 23 patients (combined group, with amyotrophic lateral sclerosis, lower motor neuron disease, and Guillain-Barré syndrome) showing raised titres against GM1 and only four of 23 (one of four patients with amyotrophic lateral sclerosis) against AGM1 and GM1. As in our sample, this may reflect heterogeneity of disease processes in motor neuron disease. Also, these findings argue against a specific pathogenetic role of antiganglioside antibodies. As was pointed out in our study, there emerge characteristic antibody patterns (in 75% of our sample of 35 patients with amyotrophic lateral sclerosis); however, we warn against considering them specific.

There is a similar debate about the role of serum antibodies in motor neuron disease and especially of antibodies to GM1: raised titres of anti-GM1 antibodies are not specific for motor neuron disease, but when there are motor symptoms, these are of the lower motor neuron disease type.^{2,3} Whereas the first studies claimed an association of GM1 antibodies and amyotrophic lateral sclerosis, Willison *et al*⁴ found in their 1993 case-control study no association of amyotrophic lateral sclerosis and antibodies to GM1. These data support our earlier findings, that GM1 may not be specific for motor neuron disease or amyotrophic lateral sclerosis¹ (in our sample only four of 35 patients with amyotrophic lateral sclerosis had serum IgM anti-GM serum antibodies). Thus to establish a possible pathogenetic or diagnostic role for these antibodies, studies with large sample size and tests for reactivity to multiple antigens are needed.⁵

- 1 Stevens A, Weller M, Wiethölter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 1993; 56:361-4.
- 2 Kinsella LJ, Lange DJ, Trojaborg W, Sadiq SA, Younger DS, Latov N. Clinical and electrophysiological correlates of elevated anti-GM1 antibody titers. *Neurology* 1994; 44:1278-82.
- 3 Kornberg AJ, Pestronk A, Bieser K, *et al*. The clinical correlates of anti-GM1 antibodies. *Ann Neurol* 1994;35(2):234-7.
- 4 Willison HJ, Chancellor AM, Patterson G, Veitch J, Singh S, Whitelaw J, Kennedy PGE, Warlow CP. Antiglycolipid antibodies, immunoglobulins, and paraproteins in motor neuron disease: a population based case-control study. *J Neurol Sci* 1993; 114:209-15.
- 5 Kornberg A, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. *Muscle Nerve* 1994;17:100-4.

Three decades of normal pressure hydrocephalus: are we wiser now?

In his excellent editorial on this subject, Vanneste¹ refers to the place of CSF removal and pressure monitoring tests in the diagnosis of normal pressure hydrocephalus, and their possible predictive role for the success of shunt procedures. With regard to lumbar CSF infusion methods, he regards their invasiveness and the need for technical expertise, as making them unsuitable for widespread clinical use.

In the early days of recognition of the syndrome, and well before the advent of modern imaging techniques, we described a simple bedside CSF manometric procedure.² This involved CSF pressure readings

after withdrawal of fluid into a syringe and its reinjection after the pressure returned to its previous level. The immediate resulting pressure rise lasted for only a few minutes in cases where normal pressure hydrocephalus was not present, but for a long period in those patients in whom the diagnosis of normal pressure hydrocephalus was considered acceptable. The assumption, in view of conceptions regarding the physiopathological basis of normal pressure hydrocephalus prevalent at the time, was that the test reflected reduced fluid reabsorptive capacity responsible for the syndrome. It would seem now that according to Vanneste's reference to modern views, the results would have to be explained somehow in terms of obstructions, either subarachnoid or intraventricular. The essential advantages of this method were of course the absence of risks associated with the introduction of any material other than the patient's own CSF, together with its technical simplicity. The possible predictive value for benefits resulting from shunt diversion was not followed up at that time.

Incidentally I think that we owe McHugh³ credit for the first report describing the clinical normal pressure hydrocephalus syndrome.

J BRAHAM
Department of Neurology,
Chaim Sheba Medical Centre,
Tel Hashomer, Tel Aviv University,
Israel

- 1 Vanneste JAL. Three decades of normal pressure hydrocephalus: are we wiser now? *J Neurol Neurosurg Psychiatry* 1994;57: 1021-5.
- 2 Brahm J, Sarova-Pinhas I, Front D, Goldhammer Y. A simple CSF manometric test for adult hydrocephalus associated with dementia. *Eur Neurol* 1971;5:294-302.
- 3 McHugh PR. Occult hydrocephalus. *Q J Med* 1964;33:297-308.

Post-traumatic syringomyelia

The excellent study of Squier and Lehr¹ reports that post-traumatic syringes based on clinical examination and spinal CT occur with an incidence of between 1.1 and 4.5%; based on MRI studies with an incidence of 12-22%. Their own pathological findings in 20 spinal cords examined between two days and 43 years after severe spinal injury yielded four cases (20%) with cysts extending at least two segments from the site of original trauma. The table summarises the positive results.

Time after injury	Level of initial cord lesion	Extent of pathological syrinx
6 weeks	T5	T5-T8
12 weeks	C7	C4-C7
22 years	T12	T10-T12
34 years	L3	C8-L3

Before we accept the important inferences suggested by these data, we should examine the defining criteria. The authors do not provide clinical data to establish to what extent, if any, their four patients had clinical signs of a syrinx. A mixture of myelomalacia, fibrillary gliosis, and often cystic change is found at the level of injury in all cases after the first few months, and

extends locally, rostrally, and/or caudally in relation to the severity and extent of the softening, infarction, and atrophic damage. Any persisting bone fragments or malalignment may increase the size of the cord damage and cyst formation.

The criterion of a cystic cavity extending for at least two segments is, I suggest, arbitrary. For if we took the defining limit as more than three segments, the incidence would be one in 20 (5%), a figure roughly that previously accepted for clinical post-traumatic syringomyelia. This single case survived 34 years from an injury at the age of 25. It may be that many patients with an extensive syrinx shown at MRI have no clinical signs, and we do not know how long it takes for the MR image of a syrinx to become symptomatic; indeed in some such injuries in middle aged and elderly people it is likely that the syrinx may never cause appreciable symptoms or deterioration of neurological function. The medicolegal implications are self evident.

J M S PEARCE
304 Beverley Road
Anlaby
Hull HU10 7BG, UK

- 1 Squier MV, Lehr RP. Post-traumatic syringomyelia. *J Neurol Neurosurg Psychiatry* 1994;57:1095-8.

Verbal fluency in cortical and subcortical dementia

In a recent issue Rosser and Hodges¹ have presented some potentially interesting data relating to measures of verbal fluency in patients with Alzheimer type dementia, Huntington's disease, and progressive supranuclear palsy. Their main finding is unfortunately dubious in view of an inappropriate statistical analysis.

The effect being sought by Rosser and Hodges¹ and which they claim to have found, is a differential pattern of impairment across different measures of fluency between the different patient groups. To confirm what they were seeking in statistical terms requires as an essential minimum the demonstration of a significant interaction between the patient groups and type of measure. In their investigation they have employed four separate groups (including a control group as well as the three patient groups already mentioned) with patients in each of these being tested on three separate fluency measures. This corresponds to what is commonly described as a split plot analysis of variance model² having both within subject and between subject effects. Data obtained in accordance with this model and subjected to an appropriate analysis do enable the computation of a groups $\times$ measures interaction.

By contrast what Rosser and Hodges¹ report for their statistical analyses are three one way analyses of variance carried out independently on each of the three measures with these followed by post hoc comparisons of particular pairs of groups. Apart from possibly being unsuitable in other ways, this form of analysis does not permit the computation of interaction terms. It is also possible for the effects described as emerging from these analyses to appear and yet to find that the more appropriate analysis fails to achieve the

critically significant groups $\times$ measures interaction.

The effect that Rosser and Hodges claim may well be present in their data and, if so, would help to contribute to the understanding of the relation between allegedly cortical and subcortical dementias. Unfortunately the analyses actually reported do not properly permit the suggested conclusion to be drawn and it would therefore be useful to know if the relevant interaction really is significant.

E MILLER
Department of Psychology
(Clinical Section),
University of Leicester,
Leicester LE1 7RH, UK

- 1 Rosser A, Hodges JR. Initial letter and semantic category fluency in Alzheimer's disease, Huntington's disease, and progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* 1994;57:1389-1394.
- 2 Winer JB. *Statistical principles in experimental design*. 3rd ed. New York: McGraw Hill, 1991.

Hodges replies:

We are very grateful for Miller's comments on our paper. We have now performed a split plot analysis of variance with both within subject and between subject effects, which confirmed the presence of a significant interaction (F (df 51,3) = 19.6, $P < 0.001$). This highly significant group conditions interaction confirms the differential effect of Alzheimer's disease *v* Huntington's disease and progressive supranuclear palsy on category and letter based fluency tests, which we hope will convince Professor Miller.

J R HODGES
Department of Neurology,
Addenbrooke's Hospital,
Hills Road, Cambridge CB2 2QQ, UK.

Jarisch-Herxheimer reaction in a patient with neurosyphilis: non-convulsive status epilepticus?

In their lesson of the month Zifko *et al*¹ described a patient with neurosyphilis who developed fluctuating consciousness, disorientation, restlessness, and fever 10 hours after starting intravenous penicillin G. He had tachycardia and hyperhydrosis. An EEG showed generalised 3/s rhythmic activity (periodic lateralised epileptiform discharges). These findings were attributed to a Jarisch-Herxheimer reaction.

We suggest that non-convulsive status epilepticus is an alternative explanation. Altered consciousness and prolonged confusion are the central clinical findings of non-convulsive status, which may occur without preceding or accompanying generalised tonic clonic seizures, may resolve spontaneously, and may be associated with the autonomic symptoms of fever and tachycardia.^{2,3} Periodic lateralised epileptiform discharges are one of the EEG correlates of non-convulsive status.⁴ As stated by the authors, patients with neurosyphilis are susceptible to epileptic seizures, both due to the condition itself⁵ and due to a Jarisch-Herxheimer reaction. In addition, penicillin

itself may precipitate seizures.⁶ In their patient, non-convulsive status may have been evoked by one of these mechanisms. It would be of value to know whether patients such as this respond to antiepileptic medication.

N HEYE
J W DUNNE
Royal Perth Hospital,
GPO Box X2213, Perth,
Western Australia, Australia

- 1 Zifko U, Lindner K, Wimberger D, Volc B, Grisold W. Jarisch-Herxheimer reaction in a patient with neurosyphilis. *J Neurol Neurosurg Psychiatry* 1994;57:865-7.
- 2 Dunne JW, Summers QA, Stewart-Wynne EG. Non-convulsive status epilepticus. A prospective study in an adult general hospital. *Q J Med* 1987;62:117-26.
- 3 Cascino GD. Non convulsive status epilepticus in adults and children. *Epilepsia* 1993;34 (suppl 1):S21-28.
- 4 Grand Maison F, Reiher J, Leduc CP. Retrospective inventory of EEG abnormalities in partial status epilepticus. *Electroencephalogr Clin Neurophysiol* 1991;79:264-70.
- 5 Radhakrishnan K, Ashok PP, Sridharan R, El-Mangoush M. Periodic pattern in meningovascular syphilis. *J Neurol Neurosurg Psychiatry* 1984;47:1360-1.
- 6 Davies DM. *Textbook of adverse drug reactions. Chapter 18. Neurological disorders*. 3rd ed. Oxford: Oxford University Press, 1985:495.

Zifko *et al* reply:

We appreciated the interesting response of Dune and Heye to our article. Although we cannot completely exclude the possibility of non-convulsive status epilepticus in our patient, we have several arguments that make their theory unlikely.

Firstly, autonomic symptoms of fever and tachycardia in our patient occurred before onset of confusion and altered consciousness, and were not present during the period of disorientation and psychomotor restlessness, as mentioned in the text. Secondly, although periodic lateralised epileptiform discharges may be a sign of non-convulsive status, this abnormality is non-specific. Thirdly, during CT, psychomotor restlessness was treated with 70 mg intravenous diazepam, which did not affect the confusion. Non-convulsive status of complex partial type usually responds well to diazepam.

U ZIFKO
K LINDNER
W GRISOLD
Department of Neurology,
Kaiser Franz Josef Spital,
1100 Vienna, Austria

Risperidone in Parkinson's disease

A recent, excellent review of the management of Parkinson's disease called attention to the atypical neuroleptic drug clozapine (an antagonist of dopamine D₁ and serotonin 5HT₂ receptors) for amelioration of psychotic symptoms derived from dopaminergic treatments, when temporary withdrawal of antiparkinsonian drugs fails.¹ Small doses of the atypical neuroleptic drug risperidone (0.25-1.25 mg/day) can also be used for ameliorating hallucinations induced by levodopa without worsening motor symptoms in Parkinson's disease.² Risperidone has a strong affinity for 5HT₂ receptors and only moderate affinity for D₂ receptors. For parkinsonian patients in

whom the 1-2% risk of agranulocytosis with clozapine is unacceptable, risperidone is another option.

ALMIR R TAVARES, JR
UFMG School of Medicine,
Belo Horizonte, Brazil

- 1 Marsden CD. Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1994;57:672-81.
- 2 Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. *Lancet* 1994;343:1370-1.

CORRECTION

Rajsheshkar V. Benign thalamic cyst presenting with contralateral postural tremor. *J Neurol Neurosurg Psychiatry* 1994;57:1139-40.

During production, the figure was incorrectly printed. The correct version is given here.

T1 weighted axial (A) and sagittal (B) MRI of the patient showing the hypointense cystic lesion in the right thalamus and basal ganglia. Compression of the upper midbrain by the mass is evident in the sagittal scan.